tbuckley/cabot-search huggingface dataset:
Careful Decoy Receptor Titering is Required to Inhibit Tumor Angiogenesis While Avoiding Adversely Altering VEGF Bioavailability
Authors: Andrew M. Davidoff, Catherine Y.C. Ng, Youbin Zhang, Christian J. Streck, Stephanie J. Mabry, Susan H. Barton, Troy Baudino, Junfang Zhou, Robert S. Kerbel, Elio F. Vanin, Amit C. Nathwani
Journal: Molecular Therapy (2004)

To inhibit tumor-induced angiogenesis, the VEGF signaling pathway was targeted using AAV vectors encoding a VEGF decoy receptor, a truncated, soluble form of the murine VEGF receptor-2 (tsFlk-1). This approach initially had significant anti-neuroblastoma efficacy in murine xenograft models of local and metastatic disease, but when higher circulating levels of tsFlk-1 were established, tumor growth was more aggressive than even in control mice. Part of the mechanism for this apparent tumor resistance was increased human VEGF expression by the tumor cells. However, further investigation revealed that although a greater amount of VEGF could be bound by higher levels of tsFlk-1, more VEGF also existed in an unbound state and was, therefore, available to support angiogenesis. This novel, tumor-independent mechanism for resistance to antiangiogenic strategies suggests that careful titering of angiogenesis inhibitors may be required to achieve maximal antitumor efficacy and avoid therapy resistance mediated, in part, by ligand bioavailability. This has important implications for therapeutic strategies that use decoy receptors and other agents, such as antibodies, to bind angiogenic factors, in an attempt to inhibit tumor neovascularization.
The Twin Cities' Medical Marketplace
Authors: John K. Iglehart
Journal: New England Journal of Medicine (1984)

In an era when federal and state policies increasingly dictate the direction of change in medical-care delivery and payment, the Twin Cities of Minnesota stand out as a metropolitan area where private-sector interests have been the leading architects of a redesigned health-care landscape. Driven by the philosophical conviction that resources can be better allocated through adherence to market principles than through government regulation and by a strong practical instinct to survive, the health-care providers and insurers of Minneapolis–St. Paul are locked in a competitive struggle for patients. The competition is taking place in an area that has more doctors and . . .
Marginal Cardiac Allografts Do Not Have Increased Primary Graft Dysfunction in Alternate List Transplantation
Authors: Brian Lima, Keshava Rajagopal, Rebecca P. Petersen, Ashish S. Shah, Beth Soule, G. Michael Felker, Joseph G. Rogers, Andrew J. Lodge, Carmelo A. Milano
Journal: Circulation (2006)

Clinical success with modern heart transplantation (HT) has led to the development of an alternate list (AL) HT strategy, matching marginal cardiac allografts with recipients who do not meet standard criteria for HT. Marginal allografts may be at an increased risk for primary graft dysfunction (PGD), the leading cause of early mortality after HT.(1) The incidence of PGD in AL HT relative to standard list (SL) HT has not been evaluated, and may contribute to the greater mortality associated with AL HT.(2) The objective of this study was to determine the incidence of and predictors for PGD.A retrospective analysis was performed on 260 consecutive adult patients undergoing either SL HT (n=207) or AL HT (n=53) at our institution from 1/2000 to 1/2005. PGD was defined by requirement for mechanical circulatory support immediately post-HT or more broadly as the need for either mechanical support or high-dose inotrope (epinephrine > or = 0.07 microg/kg/min). Donor hearts allocated to AL recipients were turned down for SL HT for reasons that included coronary disease, left ventricular dysfunction or hypertrophy, and high-dose inotropic requirement. AL HT recipients were significantly older, with a higher proportion of diabetes mellitus and ischemic cardiomyopathy. Both groups experienced a similar incidence of significant rejection, but overall mortality was higher in the AL HT group. (2) The incidence of PGD did not differ between AL and SL HT recipients. Pre-transplant VAD and prolonged total ischemic times (> or = 4.5 hours) were independent predictors of PGD.Select marginal donor hearts used in AL HT do not have an increased incidence of PGD. Pre-transplant VAD and prolonged ischemic times are more important determinants of PGD. These data support continued aggressive utilization of marginal donor hearts in AL HT.
Improved Endoscopic Management of Severe Upper Gastrointestinal Hemorrhage Using a New Wide-Channel Endoscope
Authors: R. E. Hintze, K. F. Binmoeller, A. Adler, W. Veltzke, F. Thonke, N. Soehendra
Journal: Endoscopy (1994)

Problems in emergency endoscopy for upper gastrointestinal bleeding may arise due to blood and food debris preventing proper endoscopic vision and orientation. We present here a new big channel endoscope with a 6 mm suction and drainage channel that achieved complete evacuation of stomach contents in 122 of 123 patients with upper gastrointestinal bleeding, in whom complete gastric cleaning and identification of the bleeding source had proved impossible using standard endoscopes. Gastric emptying using the big-channel endoscope was possible within five minutes in all successful cases. Optimal conditions for therapeutic procedures were therefore provided. The size of the instrumentation channel may open up new indications also for non-emergency endoscopic diagnosis and treatment.
Use of the general health questionnaire in clinical work.
Authors: D Goldberg
Journal: BMJ (1986)

Mechanical ventilation (MV) may lead to ventilator-induced diaphragm dysfunction (VIDD). VIDD is associated with difficult MV weaning and longer MV duration. Mitigating VIDD may thus improve outcomes in patients on prolonged MV. We conducted a preliminary multicenter, open label, randomized controlled trial of temporary transvenous diaphragm neurostimulation (TTDN) using a multi-electrode stimulating central venous catheter (Lungpacer Diaphragm Pacing Therapy System) in difficult-to-wean MV patients. Patients on MV for &gt;96 hours with at least two failed spontaneous breathing trials and satisfying readiness to wean criteria were randomized (1:1) to TTDN (up to 120 stimulations per day; up to 30 days) or standard of care (SoC). Outcomes assessed included the proportion of patients successfully weaned, MV duration, 30-day survival, and maximal inspiratory pressure (MIP). 112 patients were randomized (57 TTDN; 55 SoC). TTDN was successfully delivered in 75% of cases. The frequency of serious adverse events was similar in both groups. For TTDN and SoC, respectively, the incidence of successful weaning was 82% and 74% (p=0.586); MV duration was 12.7±9.9 and 14.1±10.8 days (p=0.498); 30-day survival was 93% and 85% (p=0.216); MIP increased by 17±3 cmH2O vs. 5±2 cmH2O (p=0.001), with a significant stimulation dose-response relationship in TTDN patients. TTDN is feasible and safe in difficult to wean patients. A significant diaphragm-related improvement in MIP was achieved independent of patients9 cooperation.This study will help define the patient population and effect size to appropriately power future studies for clinical efficacy.
New Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy
Authors: Irum Khan, Jessica K. Altman, Jonathan D. Licht
Journal: Clinical Cancer Research (2012)

Although standard therapy for AML has been relatively constant over the past 2 decades, this may be changing with enhanced technologies allowing for the classification of acute myeloid leukemia (AML) into molecularly distinct subsets. Some specific subsets of AML have an excellent prognosis in response to standard therapy, whereas the poor prognosis of AML associated with specific sets of mutations or chromosomal anomalies requires the development of new therapies. Elucidation of the molecular pathogenesis of AML has led to the development of therapies that affect signaling, apoptosis, protein and intermediate metabolism, the surface of the leukemia cell, leukemia cell/stromal interaction, and epigenetic regulation of gene expression.
Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein.
Authors: B P Wallner, A Z Frey, R Tizard, R J Mattaliano, C Hession, M E Sanders, M L Dustin, T A Springer
Journal: The Journal of Experimental Medicine (1987)

We have isolated the cDNA for human lymphocyte function-associated antigen 3 (LFA-3), the ligand of the T lymphocyte CD2 molecule. The identity of the clones was established by comparison of the deduced amino acid sequence to the LFA-3 NH2-terminal and tryptic peptide sequences. The cDNA defines a mature protein of 222 amino acids that structurally resembles typical membrane-anchored proteins. An extracellular domain with six N-linked glycosylation sites is followed by a hydrophobic putative transmembrane region and a short cytoplasmic domain. The mature glycoprotein is estimated to be 44-68% carbohydrate. Southern blots of human genomic DNA indicate that only one gene codes for human LFA-3. Northern blot analysis demonstrates that the LFA-3 mRNA of 1.3 kb is widely distributed in human tissues and cell lines.
HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients
Authors: Luigi Roffi, Alessandra Ricci, Cristina Ogliari, Astrid Scalori, Eliseo Minola, Guido Colloredo, Carlo Donada, Roberto Ceriani, Gianni Rinaldi, Bruno Paris, Giovanni Fornaciari, Rino Morales, Paolo Del Poggio, Angelo Sangiovanni, Marco Buonocore, Valentina Bellia, Paolo Riboli, Maria Cristina Nava, Fabio Panizzuti, Alberto Piperno, Massimo Pozzi, Pietro Pioltelli, Giuseppe Mancia
Journal: Journal of Hepatology (1998)
Acquired port wine stains:clinical and psychological assessment and response to pulsed dye laser therapy
Authors: S.W. LANIGAN
Journal: British Journal of Dermatology (1997)

Nineteen patients are presented with acquired port wine stains. Acquired port wine stains are uncommon vascular lesions with the appearance of a congenital port wine stain but onset after birth. This is the largest group of patients reported to date. The acquired port wine stain was on the head and neck in 17 patients and in six this was associated with preceding trauma. Psychological assessments in adult patients showed similar morbidity to that seen in patients with congenital port wine stains. This morbidity was improved with successful laser treatment. Pulsed dye laser therapy resulted in complete clearance of the lesion in six (46%) of 13 patients treated. Two further patients had an excellent response.
This is medical progress? Trends and consequences of antibiotic use in the United States. In comment
Authors: M. M. Howell
Journal: JAMA (1974)

THIS IS a timely discussion of a remediable problem in present-day practice. It appears to be more an editorial than a scientific paper. As such, I am willing to concede the authors some editorial prerogative and poetic license, since I can agree from experience with most of their conclusions. I do believe that they have indulged in "overkill," and that their reasoning and quotations stretch extrapolative gymnastics to their ultimate. Their quotation from McCabe in the<i>New England Journal of Medicine</i>article, which takes a reported incidence of Gram-negative bacteremia of 1/100 in several major centers and projects 100,000 fatalities a year nationwide, approaches a journalistic quality usually reserved for medical articles in lay magazines. In another instance they suggest, without producing substantiating evidence, that the rate of adverse antibiotic reactions may be the same in ambulatory patients as that already documented in hospitalized populations. As a physician who has
Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia
Authors: D Heim, D Friess, S Christen, G Stüssi, S Meyer-Monard, A Tichelli, J R Passweg, A Gratwohl
Journal: Leukemia (2006)
Trichorhinophalangeal syndrome type I: symptoms and signs, radiology and genetics.
Authors: S Noltorp, U L Kristoffersson, N Mandahl, L Stigsson, B Svensson, C O Werner
Journal: Annals of the Rheumatic Diseases (1986)

The present study shows the occurrence of the trichorhinophalangeal syndrome type I in a Swedish family. Five members were affected and they were examined clinically and radiologically, and four of them were also cytogenetically examined. Three of them had dysplasia of the hip joints reminiscent of the Legg-Calvé-Perthes disease. Functional hand problems were common. High resolution G banding displayed normal chromosome complements. The inheritance was autosomal dominant. The data presented stress the importance of identifying the syndrome early in life so as to prevent the development of impaired hand and hip function.
THE DEFECTS OF THE MURPHY BUTTON, WITH SUGGESTIONS OF IMPROVEMENTS IN THE OPERATION OF GASTROENTEROSTOMY.
Authors: ROBERT. F. WEIR
Journal: JAMA (1904)

It is not proposed in this article at all to decry the merits of the well-known Murphy button, for it is conceded by everyone that by this admirable mechanical device, abdominal surgery has been largely advanced in the last decade. Since its introduction by its distinguished inventor, however, an enormous experience as to its value as well as to its demerits has been acquired, of which it is well from time to time to take stock. In the earlier anastomoses between intestine and intestine or intestine and stomach, or between the gall bladder and intestine or stomach, the usually employed incision demanded in its best digested form an opening which experience showed in a gastroenterostomy and in an enteroenterostomy should be at least two and one-half inches long to prevent its subsequent closure, and to complete the operation it was requisite that the edges of the applied gut and stomach,
Sacro-iliitis and Ulcerative Colitis
Authors: V. Wright, G. Watkinson
Journal: BMJ (1965)

BDICALJOURNAL 675 been treated surgically five had rheumatic complaints persisting after surgery.None were examples of colitic arthritis.In one patient the pains were apparently a result of sacro-iliitis which had developed during the course of the colitis.We are grateful to Professor J. C. Goligher, who allowed us to question patients under his care, and who performed most of the sigmoidoscopic examinations.Miss M. Price drew the figures.
Biochemistry and Pathology of Connective Tissue
Authors: H. R. Catchpole
Journal: JAMA (1975)

This volume presents a solid roster of Japanese investigators and their work in the area of connective tissue, a field that, after a slow start, has been increasingly cultivated in Japan since 1960. Regrettably, much of this work has not entered the general literature and it is to be hoped that the present offering will help to correct this imbalance. However, the last quoted papers are from 1971, which is an indication of considerable publication lag. This is a collection of research papers, eclectic in nature, dealing with more or less familiar topics, although work on the mucopolysaccharides of the otolaryngological division seems to have been preempted by Japanese workers. One finds some of the familiar shibboleths. Study of ultrastructure by the approved methods of fixation and staining appears to have reached a point of diminishing conceptual returns—in the West as well as in the Far East. This is a
Thrombocytopenia after a single test dose of methotrexate
Authors: Debra M. Jih, Victoria P. Werth
Journal: Journal of the American Academy of Dermatology (1998)

<h2>Abstract</h2> Low dose methotrexate (MTX) can cause numerous gastrointestinal, pulmonary, central nervous system, and hematologic toxicities. Risk factors include folate deficiency, decreased renal function, older age, increased mean corpuscular volume or concomitant use of trimethoprim-sulphamethoxazole, probenecid, or nonsteroidal antiinflammatory drugs (NSAIDs). We describe a case of isolated thrombocytopenia after a single oral dose of MTX in a 36-year-old woman with sarcoidosis. She had rheumatoid arthritis and her only other medications included NSAIDs. One week after her first oral dose of 7.5 mg MTX, diffuse petechiae developed on her chest, abdomen, and extremities; she had a platelet count of 25,000/mm<sup>3</sup> . Nine days after discontinuation of both MTX and the NSAID, her platelet count increased to 189,000/mm<sup>3</sup> . (J Am Acad Dermatol 1998;39:349-51.)
Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States.
Authors: O Wong, F Harris, T J Smith
Journal: Environmental Health Perspectives (1993)

In this study, the cohort consisted of 18,135 distribution employees with potential exposure to gasoline for at least one year at land-based terminals (n = 9,026) or on marine vessels (n = 9,109) between 1946 and 1985. The primary objective of the study was to determine the relationship, if any, between exposure to gasoline and mortality from kidney cancer or leukemia. In addition, other causes of death of secondary interest included multiple myeloma and heart diseases. The mortality of the cohort was observed through June 30, 1989. The results of this study indicated that there was no increased mortality from either kidney cancer or leukemia among marketing and marine distribution employees who were exposed to gasoline in the petroleum industry when compared to the general population. Among the land-based terminal employees, the kidney cancer standardized mortality ratio (SMR) was 65.4 (12 deaths) and leukemia SMR was 89.1 (27 deaths). For the marine cohort, the SMRs were 83.7 for kidney cancer (12 deaths) and 70.0 for leukemia (16 deaths), respectively. More importantly, based on internal comparisons, there was no association between mortality from kidney cancer or leukemia and various indices of gasoline exposure. In particular, neither duration of employment, duration of exposure, age at first exposure, year of first of exposure, job category, cumulative exposure, frequency of peak exposures, nor average intensity of exposure had any effect on kidney cancer or leukemia mortality. For acute myeloid leukemia, a nonsignificant mortality increase was found in land-based terminal employees (SMR = 150.5, 13 deaths), but no trend was detected when the data were analyzed by various gasoline exposure indices. This nonsignificant excess was limited to land-based terminal employees hired before 1948. On the other hand, a deficit of mortality from acute myeloid leukemia was observed among marine employees (SMR = 74.2, 5 deaths). For the two cohorts combined, SMR for acute myeloid leukemia was 117.1 based on 18 deaths. We did not find any relationship in our study between gasoline exposure and mortality from multiple myeloma or heart diseases. In general, we did not find any significantly increased mortality, either overall or from specific causes, associated with gasoline exposure in this study of marketing and marine distribution employees.
Adverse Effects of Dabigatran
Authors: Ryan P. Radecki
Journal: Annals of Internal Medicine (2012)

Letters18 December 2012Adverse Effects of DabigatranRyan P. Radecki, MDRyan P. Radecki, MDFrom The University of Texas Health Science Center at Houston, Houston, TX 77030.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-12-201212180-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:I thank Dr. Pazmiño for his insightful perspective about the contribution of renal insufficiency to the enhanced anticoagulant effect of dabigatran. Despite the favorable safety profile of dabigatran compared with that of warfarin shown in the RE-LY trial (1), exclusion of patients with impaired glomerular filtration rates reduces the external validity of the findings of the RE-LY investigators. This demonstrates a familiar principle in medical practice about observed discrepancies between efficacy in controlled trials and effectiveness in clinical practice.Although I agree with the theoretical utility of hemodialysis in the setting of dabigatran overdose, this reversal strategy will ...References1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. [PMID: 19717844] CrossrefMedlineGoogle Scholar2. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother. 2012;46:21. [PMID: 22872748] CrossrefMedlineGoogle Scholar3. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding [Letter]. Blood. 2012;119:2172-4. [PMID: 22383791] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Ryan P. Radecki, MDAffiliations: From The University of Texas Health Science Center at Houston, Houston, TX 77030.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2956. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDabigatran: Uncharted Waters and Potential Harms Ryan P. Radecki Adverse Effects of Dabigatran Patricio A. Pazmiño Metrics 18 December 2012Volume 157, Issue 12Page: 916KeywordsDeath ratesDisclosureExerciseGlomerular filtration rateHemorrhagePlateletsProtaminesRed blood cellsSafetyThrombin ePublished: 18 December 2012 Issue Published: 18 December 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
TCT-98 Largest Single-Center Experience of Percutaneous Left Ventricular Transapical Access for Structural Heart Disease Interventions
Authors: Chad Kliger, Leandro C. Maranan, Sonnit Sharma, Robert Kumar, Vladimir Jelnin, Itzhak Kronzon, Anja Summers, Carlos E. Ruiz
Journal: Journal of the American College of Cardiology (2013)
Is the clinical course of HIV-1 changing? Cohort study
Authors: A Sinicco, R Fora, R Raiteri, M Sciandra, G Bechis, M M Calvo, P Gioannini
Journal: BMJ (1997)

To assess whether the clinical course of HIV infection has changed from 1985 to 1995.Cohort Study.Infectious disease clinic.285 patients recruited from September 1985 to January 1995 with < or = 12 months between the dates of their last seronegative and first seropositive test result and with first follow up visit in the six months after seroconversion and at least 12 months' follow up. Patients were grouped according to the date of seroconversion.Time to CD4 cell count of < 500, 400, and 200 x 10(6) cells/l, and clinical outcome defining AIDS; variation in cell count per day between consecutive visits, and ratio between this variation and time from estimated date of seroconversion at each visit.The groups were similar in age, number with acute primary HIV infection, CD4 cell count at intake, and cell count at the beginning of antiretroviral treatment; they differed in sex ratio, risk factors for HIV, probability of CD4 cell decline to < 500, 400, and 200 x 10(6) cells/l. and risk of developing AIDS. Acute infection, seroconversion after December 1989, and serum beta 2 microglobulin > 296 nmol/l were independent predictors of poor clinical course. The speed of CD4 cell decline, expressed as cell variation divided by the number of days between consecutive visits, increased with more recent seroconversion (P = 0.02). Ratio between the speed of CD4 cell decline and time from estimated date of seroconversion at each visit was also higher in the patients who seroconverted after December 1989.The faster disease progression and the higher speed of CD4 cell decline at early stages in the patients with recently acquired HIV infection suggest changes in the clinical course of HIV infection.